





SUNPHARMA

13 December 2024


About company

Sun Pharmaceutical Industries Ltd, commonly known as Sun Pharma, is one of India’s largest pharmaceutical companies and a global leader in generic and specialty medications. Founded in 1983, it produces a wide range of products across various therapeutic areas, including psychiatry, neurology, cardiology, and gastroenterology. Sun Pharma operates in over 100 countries, with a strong presence in the U.S. market, which contributes significantly to its revenue. Known for strategic acquisitions, it has grown through mergers, including its acquisition of Ranbaxy in 2014, which boosted its global footprint.

Financials



MARKET CAP	RS 4,30,549 Cr.
P/E RATIO	38.4
DIVIDEND YIELD	0.74%
ROCE	17.3%
ROE	16.7%
FACE VALUE	1.00
3 YEARS SALES GROWTH	13%
3 YEARS PROFIT GROWTH	25%



Our recommendation

OPTIONS INSIGHT: BUY SUNPHARMA 1820 PUT ABOVE 45 TGT 55/65 SL BELOW 35

Technical analysis

Sun Pharmaceutical Ind Ltd share prices tumbles heavily since the beginning of today's session. A continuous fall from 1811 to 1774 has been seen due to negative market sentiments. The prices continuously trading below its 20 EMA level, indicating a potential of a further downside move. The prices breaks the previous support level of 1795 and sustaining below it, however that support has been broken since more than half an hour ago, buy still we expect it to continue its bearish trend till 1760. The bearish view is backed by couple of indicators, such as the prices are trading below its 20 EMA level and Supertrend indicator is showing bearish trend as red zone is active in it (as shown in image below). The prices are expect to test the next support area of 1760 level with 1795 as the resistance level. Thus, we recommend SUNPHARMA 1820 PUT options.

rumpusroom published on TradingView.com, Dec 14, 2024 11:49 UTC+5:30



Disclaimer

I, Ruchi Nahar, SEBI Registered Research Analyst (INH000014544) comply with the qualification and certification requirements under SEBI (Research Analyst) Regulations, 2014. I have qualified CA, CS and MBA, has over 11 years of experience in MNCs, culminating as Head of Finance. I now leverage my expertise to guide stock market investors with strategic insights. All of the views expressed in research reports and recommendations issued by me reflect my personal views about the subject company or companies at the given point of time and I do not receive/accept any kind of compensation, directly or indirectly related to specific recommendations or views expressed in reports issued by me. I/my relatives do not at any point of time of issuing the reports have any material conflict of interest in the subject company neither I was/am/will be engaged in market making activity for the subject company. The investments discussed or views expressed in reports and recommendations issued by me may not be suitable for all investors. The user assumes the entire risk of any use made of this information. I nor any person connected with my report, accepts any liability arising from the use of research document. The recipients of research document should rely on their own investigations and should consult their own financial advisors to determine merit and risks of such investments based on their own risk appetite. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. Reports and recommendations based on technical analysis centres on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. Opinions expressed in research reports & recommendations will be based on the current opinions as of the date appearing in research report & recommendations. While I endeavour to update on a reasonable basis the information discussed in research reports, there may be regulatory, compliance, or other reasons that prevent me from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. So far as reports include current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. Investment in securities market is subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

13 December 2024

